Related Experiment Videos
Selective sentinel lymphadenectomy: progress to date and prospects for the future
John F Thompson1, Roger F Uren, Richard A Scolyer
1Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.
Cancer Treatment and Research
|October 8, 2005
Summary
Sentinel node (SN) biopsy accurately reflects regional lymph node status for various cancers. Ongoing research aims to improve SN identification accuracy and develop less invasive assessment methods.
Area of Science:
- Oncology
- Surgical Pathology
- Medical Imaging
Background:
- The sentinel node (SN) concept, originating in the 19th century, gained clinical relevance in 1992.
- SN status is a reliable indicator of regional lymph node involvement in melanoma, breast cancer, and other malignancies.
- Advancements in lymphatic mapping have enhanced understanding of lymphatic anatomy.
Purpose of the Study:
- To review the historical development and current clinical relevance of the sentinel node concept.
- To discuss methods for improving sentinel node identification accuracy.
- To explore future directions in sentinel node assessment, including non-invasive techniques.
Main Methods:
- Preoperative lymphoscintigraphy for lymphatic anatomy insights.
- Blue dye mapping for initial SN identification.
- Intraoperative gamma probe detection of radiolabeled colloid particles.
Main Results:
- Combined use of lymphoscintigraphy, blue dye, and gamma probe is crucial for optimal SN identification accuracy.
- SN status provides significant prognostic information.
- False-negative rates are increasing with extended follow-up, necessitating further research.
Conclusions:
- Sentinel node biopsy is a validated technique for staging regional lymph nodes in various cancers.
- Further research, including randomized trials, is needed to determine the therapeutic value of selective sentinel lymphadenectomy.
- Minimally invasive and non-invasive SN assessment methods, such as proton magnetic resonance spectroscopy, are future goals to reduce morbidity and cost.